Introduction
The bacterially deriyed immunosuppressants FK508 and rapamycin have proved to be useful tools for dissecting the signaling pathways that result in resting T cells making a commitment to divide (Schreiber, 1992) . This process requires two distinct signals delivered in tandem. Signals emanating from the T cell receptor (TCR) render the cell competent for cell division by establishing a second, autocrine signaling pathway involving interleukin-2 (IL-2) and the IL-2 receptor (IL-2R). Signals from the IL-2R commit the cell to a program of cell division by communicating with components of the cell cycle machinery necessary for DNA replication. Although both FK508 and rapamycin inhibit the ability of T cells to divide by binding to the same immunophilin receptor (FKBP12), the resulting complexes target different signaling pathways. inhibits the TCR signaling pathway by binding to and inhibiting the phosphatase activity of calcineurin, one of the components of the TCR pathway; a second immunosuppressant-immunophilin complex, cyclosporin-cyclophilin, also inhibitscalcineurin (Liu et al., 1991) . In contrast, FKBPIPrapamycin inhibits the IL-2R signaling pathway by binding to a 289 kDa kinase named FRAP in humans and RAFT in rats (Brown et al., 1994; Sabatini et al., 1994; Chiu et al., 1994) . In effect, the immunosuppressants have two protein-binding surfaces that mediate the heterodimerization of target proteins (immunophilins and the signaling proteins calcineurin and FRAP) and can, thus, be considered as analogous to proteins such as Grb2, which heterodimerize their targets.
Although the rapamycin-sensitive target was first examined in T cells, it is used by many eukaryotic cells to communicate changes in cell growth circumstances to the cell cycle machinery necessary for DNA replication. For example, low concentrations of rapamycin induce Gl cell cycle arrest in yeast. Genetic studies in the yeast Saccharomyces cerevisiae identified two related genes, TO/?7 and TOR2, containing apparent open reading frames encoding 2470 amino acids and 2474 amino acids, respectively (Heitman et al., 1991; Cafferkey et al., 1993; Kunz et al., 1993; Helliwell et al., 1994) . The highest degree of similarity, with over 80% amino acid identity, resides in their C-termini, which are related to the catalytic domains of phosphatidylinositol (PI) kinases. This C-terminal kinase domain is interchangeable between TOR7 and TOR2, suggesting they have similar functions (Helliwell et al., 1994) . That the proteins themselves have distinct functions is evident from studies of the for7 null mutant, which has only a partial growth defect under normal growth conditions, and the for2 null, which has a lethal phenotype with cells arrested randomly in the cell cycle. Like treatment with rapamycin, the for7 tor2 double disruption results in Gl arrest (Kunz et al., 1993; Helliwell et al., 1994) . When the conserved serine residues, Ser-1972 in 7OR7 and Ser-1975 in TOR2 , are changed to isoleucine or arginine, either gene confers dominant rapamycin resistance.
The C-terminal kinase domains in FRAP and TOR are more than 80% identical. The substrate(s) of these domains has not yet been identified, despite their apparent similarity to the PI3-kinase (Pl3K) and PICkinases (Pl4K). The two cloned Pl3Ks, the ~110 Pl3K in mammals and Vps34 in yeast, also have protein kinase activity (Dhand et al., 1994; Stack and Emr, 1994) . Although the consequences of the two kinase activities are currently unknown, roles have been established for these proteins in several signaling pathways, including mitogenic pathways (for reviews see Carpenter and Cantley, 1990; Divecha and Irvine, 1995) .
In this study, we show that TORl binds directly to and that a small region surrounding Ser-1972, the FKBPl2-rapamycin-binding (FRB) domain, is sufficient for mediating this interaction. Substitution of Ser-1972 with residues larger than serine abolish this interaction both in vivo and in vitro and confer dominant rapamycin resistance, although substitution with alanine does not. Genetic analyses indicate that the kinase domains in both TOR proteins are required for their rapamycinsensitive Gl functions. Point mutations that inactivate known PI and protein kinases (kinasedead mutations) were found to abolish the ability of the TOR mutants at Ser-1972 (TOM) and Ser-1975 (TOR2) to allow growth in the presence of rapamycin and to abolish the ability of one of these, TORl (Ser-1972+le) , to produce a unique, dominant cell growth inhibitory phenotype when overproduced. Furthermore, overproduction of a TOR kinasedead mutant causes Gl cell cycle arrest. These results establish that the kinase domains of TOR proteins are essential for Gl cell cycle progression in yeast. We also show that a function of TOR2 that is required for cell viability, the essential function, is dependent on a functional TOR kinasedomain. This essential function is nonetheless resistant to the actions of rapamycin, in contrast with its Gl function. The results suggest that FKBPl2-rapamycin may interfere with the binding or phosphorylation of Gl effecters only, rather than inhibit the kinase activity of TOR proteins in a general way. These studies indicate that the TOR/FRAP proteins define a novel family of kinases and that the kinase domains of these proteins are essential for their cellular functions.
Results

TOM Binds to Yeast FKBPlP-Rapamycin Both In Vivo and In Vitro
Two mammalian homologs of TOR proteins, FRAP and RAFT, have recently been purified using FKBPl2-rapamycin affinity matrices (Brown et al., 1994; Sabatini et al., 1994) . We have used a similar strategy to examine whether TORl and TOR2 proteins bind directly to the yeast FKBPlP (yFKBPlP)-rapamycin (using glutathione S-transferase [GSTj-yFKBP12 fusion protein complexed to rapamycin; yGFK-rapamycin) complex. A single, apparently low abundance polypeptide of M, 220,999 from crude yeast lysates was specifically retained on a yGFKrapamycin column, but not to yGFK-FK506 or yGFK alone ( Figure 1A ). The gel mobility of the yeast protein is similar to that of human FRAP (Brown et al., 1994) suggesting the proteins are related. Indeed, the 220 kDa protein was recognized specifically by an anti-TORl immune serum, but not the preimmune serum on a Western blot ( Figure  1B ). We generated yeast mutants carrying the chromosomal mutations Ser-1972+Arg in TO/W or Ser-1975wArg in TOR2 by homologous recombination. The Ser-1972 mutation in TORl abolished the binding of this protein to yGFK-rapamycin in two independent mutant strains, while no effect was observed with the TOR2 mutant strains (Figure 1C) . Thus, the 229 kDa protein purified by yGFKrapamycin appears to be TORl , and mutation at Ser-1972 prevents its binding to yFKBPlP-rapamycin.
Since a TOR2 fragment has been shown to bind to FKBP12-rapamycin in a yeast two-hybrid assay (Stan et al., 1994) TOR2 most likely also binds; our inability to detect such binding in the TORl mutant strains may be due to its low level of expression.
Deletional analyses using an in vitro transcription-translation system (rabbit reticulocyte lysates) indicate that TORl with a C-terminal truncation up to amino acid 2157 After extensive washing, samples were eiuted with 1 M NaCI. The eluants were incubated with 0.7 pM yGFK alone, yGFK-FK599, or yGFK-rapamycin and were allowed to bind to a gtutathione S-Sepharose (GTS) column. The GTS-bound material was washed, eluted into SDS gel sample buffer, separated by7.5% (A, top, and S)or 2o% (A, bottom) SDS-polyacrylamide gel electrphoresis, and analyzed by silver staining (A), by immunoblot with anti-TORI immune serum (B, top) or with preimmune serum (6. bottom) as a control. (C) TORl (Ser-1972+Arg) does not bind to an FKBPlP-rapamycin complex. The following haploid yeast strains were used for the yGFKrapamycin binding assay: wild type (MATa, TO/V, TOR2), two independent clones (TOR7-7 and TOM-2) of the mutant (MATa, TOP7 [Ser-1972*Arg], TOR2), and two independent clones (TOR2-1 and TOff2-12) of the mutant (MATa, TOR7, TOP2 [Ser-1975+Arg] ).
The purification procedure is the same as Figure IA . The final yGFK-or yGFKrapamycin-bound materials were analyzed by silver staining.
is able to bind to yGFK-rapamycin. A further removal of 21 amino acids abolishes this binding ( Figure 2A ). We found a 45 kDa fragment of TORl (TORl-45, amino acids 1775-2157) containing Ser-1972 was sufficient to bind to yGFK-rapamycin.
Two naturally selected dominant rapamycin-resistant mutations at Ser.1 972, arginine and isoleucine, disrupt yGFK-rapamycin interaction wfth TOR145 completely. Similarly, glutamic acid, a residue potentially analogous to phosphoserine, also abolishes the ability of TOR1-45 to bind yGFK-rapamycin.
In contrast, alanine, a potential mimic of unphosphorylated serine, does not affect yGFK-rapamycin binding ( Figure 28) . (A) A series of "S-labeled TORI deletional mutants was generated in vitro, incubated with 0.7 PM yGFK or yGFK-rapamycin, and purified onto GTS columns. The GTS-bound materials were eluted into SDS protein gel sample buffer, separated on SDS protein gels, and analyzed by X-ray autoradiography.
Bars -1972+Arg, Ser-1972 mutants, which fail to bind to FKBP12-rapamycin, were able to resist rapamycin (Table 1 ). In contrast, the Ser-1972eAla mutant, which retains the ability to bind FKBPlP-rapamycin, was unable to confer resistance to rapamycin. When the FRB domain-containing TOR145 is overproduced, yeast cells were able to grow normally in 100 nM rapamycin, a concentration at which the growth of normal yeast cells is completely inhibited ( Figure 2C ). In contrast, cells expressing TOR145 (Ser-1972-Arg) , a mutant that does not bind yGFK-rapamycin in vitro, are sensitive to rapamycin ( Figure 2C) The analogous kinase-dead mutations were shown previously to abolish the activities of Pl3K and Vps34, respectively (Schu et al., 1993; Dhand et al., 1994) , and we have shown that similar mutations in FRAP abolish a serine-autophosphorylation activity in wild-type FRAP and its Ser-2035 (corresponding to Ser-1972 in TORl) mutant expressed in mammalian (E. J. Brown, P. A. Beal, J. Chen, T.-B. Shin, and S. L. S., unpublished data) and Sf9 cells (P. A. Beal, C. Keith, and S. L. S., unpublished data). However, we have not been able to obtain conclusive biochemical evidence for a protein kinase activity in wild-type TORl expressed in yeast cells. It is possible that the autophos-TOR145 FRBdomain was assayed for rapamycin sensitivity. TOR1-45 (FRB) expression is under the control of the GAL1 promoter (GAL, 2 PM. MA). Yeast cells were streaked onto uracildropout plates containing glucose or galactose supplemented with or without 100 nM rapamycin, and incubated at 30% for 3 days. Rapamycin resistance was scored by the ability of the cells to form colonies. A, control; 8, wild-type TOR1-45 (FRB); C, Ser-1972+Arg mutant TOR145 (FRB). proteins, and we find that the cellular effect of the mutations discussed above correlate precisely with their effect on the protein kinase activity observed with FRAP. Both TORl kinasedead mutations abolish the ability of the Ser1972+lle mutant to confer dominant rapamycin resistance when the double mutants (Ser-1972+lle/Arg-22764Pro and Ser-1972+lle/Asp2294+Glu) were expressed at low levels in glucose medium ( Figure 3A ). Similar effects were also seen with the Ser-1972+Glu and the Ser-1972+Arg double mutants (Table 1) . It was previously established that the C-terminus of both 7OR7 and TOR2 are functionatly interchangeable (Hetfffll et al., 1994) . We engineered chimeric TOR proteins comprising the N-terminus of TOR2 and C-terminus of TORl. The wild-type chimeric TORP-TORl protein (CEN4, LEU) complements the for2 null strain, showing that it is an active and functional protein and confirming the earlier report (Helliwell et al., 1994 ; see Figure 6 ). However, the two kinasedead mutations abolish the ability of the serine TOR2 mutant to resist the actions of rapamycin ( Figure 36 ). Kinasedead mutants of protein kinases often exhibit a dominant negative effect on growth by interacting in a nonproductive way with effector proteins normally associating with the wild-type kinase. We found that the Arg2276ePro and the Asp-2294-01~ TORI mutants, when overproduced following gala&se induction, inhibii growth of yeast cells cultured on solid (but not liquid) medium as shown in Figure 4 ; ffow cytometric analysis revealed these cells undergo Gl cell cycle arrest (data not shown). This observatii indicates that the kinasedead TORl proteins exhibit a dominant negative effect on TORl function. Since the tori null mutation alone does not cause Gl arrest, the dominant negative TORI mutants must interfere with the Gl functions of both TOR proteins.
An Intact Kinase Domain Is Also Required for the Ser-1972-Ne Mutatlon in TORl to lnhlbit Cell Growth Oomirmtly When tested for rapamycin sensitivity under galactose induction, the TORl (Ser-1972+lle) mutant prevented growth of yeast cells in a rapamycin-independent manner, even Figure 5 ). In contrast, the growth of yeast ceils overexpressing the TOFU (Ser-1972*lle) protein was significantly diminished. This dominant growth-arresting effect is dependent upon the existance of an intact kinase domain. When the kinase-inactivating mutations Arg-2276+Pro or Asp2294+Glu
were introduced into TORl (Ser-1972+le), the dominant growth inhibitory effect of the Ser-1972~lie mutation was lost ( Figure 5 ). This difference in growth inhibition is not due to a higher level of TOR protein expression by the TORl (Ser-1972+lle)-expressing cells, as judged by Western blots (data not shown). This growth-arresting phenotype of the TOR7 (Ser-1972-118) allele is clearly different from the dominant negative effects seen with kinase-dead TORl mutants. The TORI (Ser-1972+lle) mutant allele appears to preserve all the normal function of wild-type TOR, as evidenced by its ability to resist the actions of rapamycin and by its ability to complement the tor2 null as a chimeric protein with a TOR2 N-terminus. In addition, the dominant negative effect of the kinase-dead TORI mutants is seen only on solid medium. In contrast, overexpression of TORl (Ser-1972-,lle) causes cell growth arrest in both liquid ( Figure 5 ) and solid (data not shown) cultures. The effects of overexpression of TORl (Ser-1972*lle) mutant on cell cycle progression and checkpoints are currently under investigation.
TOFU Has an Essential Function That Is Not
Inhibitable by FKBP12-Rapamycin To investigate whether the function of TOR2 is sensitive to the actions of rapamycin, we engineered a tori null strain by inserting a LEU2 marker into the Bamlil site of TOR7 gene in the kinase domain ( Figure 6A ). This insertion has been shown previously to knock out the function of the TOR7 gene (Kunz et al., 1993; Helliwell et al., 1994) . The Ator7 strain was found to undergo Gl cell cycle arrest when treated with rapamycin, indicating that the TOR2 protein is a target of the actions of rapamycin in vivo (Figure 6A) . Despite the fact that a tor2 disruption in a wild-type TOR7 background is lethal, the TO/?7 (Ser-1972-Arg) mutant allele allows yeast to grow in the presence of rapamycin. These observations suggest that if rapamycin inhibits all functions of TOR2, then the TORl (Ser-1972-+Arg) mutant, but not the wild-type TORI, causes a gain of TORl function that should complement the for2 null lethal phenotype. We tested this by disrupting the TOR2 gene either in a wild-type TOR7 or a TO/37 (Ser-1972*Arg) mutant background ( Figure 6B ). First, diploid heterozygous TO/W for2 mutants in either a wild-type TOR7i7OR7 or mutant homozygous TOR7SRITORl SR background were generated by inserting a LEU2 marker into the BamHI site in the kinase domain previously shown to inactivate the TOR2 gene (Helliwell et al., 1994) . Tetrad analyses showed that in both genetic backgrounds, only two or less viable spores (versus four) were obtained (Figure 68) . None of the viable spores were found to cosegregate with the LEUP marker, indicating that in either genetic background, the for2 disruption is lethal. This result demonstrates that the TORl (Ser-1972+Arg) mutation does not complement the lossof theTOR2essentialfunction.
Given the dominant rapamycin-resistant phenotype of this TORl mutation and the sensitivity of TOR2 to rapamycin, we conclude that the essential function of TOR2, in contrast with its Gl function, is not inhibited by FKBP12-rapamycin. This is consistent with the observation that treating the tori null strain described above with rapamycin resulted in Gl cell cycle arrest, which is in contrast with the random cell cycle arrest phenotype observed with the tor2 null strain. Since the specificity of the essential function of TOFt2 is determined by its N-terminus (Helliwell et al., 1994) , we asked whether this essential function requires a functional kinase domain. We established diploid yeast strains with a heterozygous insertion of a URA marker into the BamHl site of the TOR2 gene (TOR2/?or2). Piasmids expressing extrachromosomal (CEN4, LEU2) TOR2, TOR2-TOM, TOR2-TORl(SI), TORP-TORl(DE), TOR2-TORl(SI/DE) were then introduced into the heterozygotes. After sporulation, we examined how the LEU2 and URA markers associate in the viable spores. Of the -40 viable spores showing LEU2 prototrophy for each strain, half were found to have the URA marker for cells expressing TOR2, TOR2-TORl, and TOR2-TORl(SI), but none were found to have the URA marker with cells expressing the kinase-dead TOR proteins ( Figure 6C ). Thus, the essential function of TOR2 requires a functional kinase domain. Discussion TOR7 (or DRR 7) and TORP(or DRR2) genes were originally isolated as mutations at a conserved residue, Ser-1972 in TORl or Ser-1975 , that confer a dominant rapamycin-resistant phenotype in yeast (Cafferkey et al., 1993; Helliwell et al., 1994 ). Our results demonstrate that TOR proteins are direct targets of FKBPl2-rapamycin. TORl and TOR2 (this study) and their mammalian homologs FRAP (Brown et al., 1994) and RAFT (Sabatini et al., 1994) bind directly to the FKBPl P-rapamycin complex during in vitro purification or in a two-hybrid yeast screening (Chiu et al., 1994) . Isorapamycin, a rapamycin derivative that binds FKBP12 with high affinity but is a poor inhibitor of cell cycle progression, binds less efficiently to both FRAP (Brown et al., 1994) and TORl (X.-F. Z. and S. L. S., unpublished data). Mutational analyses indicate that the conserved residues, Ser-1972 in TORl and Ser-1975 in TOR2, are essential for interaction with FKBP12-rapamycin in both our in vivo and in vitro binding studies. The steric requirements for this residue are highly stringent. Serine and alanine are permissive for the binding of FKBPl2-rapamycin, whereas larger residues abolish this interaction. These binding results correlate well with the ability of mutant TOR proteins to resist the inhibitory actions of rapamycin. Mutations that disrupt binding of FKBP12-rapamycin to TOR proteins confer rapamycin resistance in an in vivo assay. In contrast, the Ser-1972+Ala mutant, which binds FKBP12-rapamycin, is as sensitive to rapamycin as wild-type TORl . On the other hand, the gene encoding the Ser-1972+Ala mutant appears to have normal TOR7 function, as shown by its ability to complement the temperature sensitivity of a tori mutant strain (Table 1) pressed, this domain also allows cells to resist the actions of rapamycin, indicating that such binding occurs in vivo. In contrast, when the domain containing the Ser-1972+Arg mutation that disrupts binding to FKBPlP-rapamycin in vitro is overexpressed, it does not produce the rapamycinresistant phenotype. Together, these results establish that binding to the FRB domain is essential for the Gl inhibitory function of FKBPlP-rapamycin and that the conserved serine residue is critical for this interaction.
PI kinases and their phospholipidderived products have been shown to be important in a variety of cellular processes, including mitogenic signaling pathways (for reviews see Carpenter and Cantley, 1990; Divecha and Irvine, 1995 Ser-1972 /Ser-1975 mutants also have protein kinase activity.
In this study, w& have taken a chemical/genetic approach to study the role of the kinase domains in mediating TOR functions. Rapamycin, which causes Gl cell cycle arrest in yeast, has been used as a chemical equivalent of a loss-of-function conditional allele of TOR proteins: its inclusion in functional experiments results in the loss-offunction of endogenousTOR proteins. Since the Ser-19721 Ser-1975 TOR mutants described above do not bind FKBPl P-rapamycin, they have been used in the presence of rapamycin to assess the functional role of TOR kinase domains. We find that kinasedead mutations analogous to those that inactivate the lipid and protein kinase activity of PI kinases, and the protein kinase activity of FRAP, abolish the ability of the dominant rapamycin-resistant mutations in both TORl and TOR2 to resist the actions of rapamycin. These experiments with double mutants establish that an intact kinase domain is essential for the Gl functions of both TOR proteins. In addition, when overexpressed, the kinase-dead single mutants of TORI mentioned above show a dominant negative phenotype, resulting in Gl cell cycle arrest of yeast growing on a solid medium. Since TORl and TOR2 appear to have redundant Gl functions, the kinasedead TORl protein may bind to the Gl effecters common to TORl and TOR2, inhibiting the action of both wild-type proteins.
In experiments that do not rely upon the actions of rapamycin, we found that overproduced TORl (Ser-1972+lle), but not the wild-type or TORl (Ser-1972-+Ala) mutant proteins, dominantly inhibits cell proliferation by a mechanism that is also dependent upon its kinase domain ( Figure 5 ). Although we have not fully characterized the resulting phenotype, preliminary experiments suggest that overexpression of this Ser-1972 mutant may interfere with the function of a cell cycle checkpoint (X.-F. 2. and S. L. S., unpublished data). The TORl (Ser-1972+lle) mutant appears to preserve the normal functions of the wild-type protein, as it allows cells to resist rapamycin dominantly, it suppresses the temperature sensitivity of a for7 mutant (Table  l) , and its C-terminal domain (including the kinase and mutant FRB domains) provides the essential TOR2 function when fused to the N-terminal domain of TOR2. Thus, growth inhibition is not due to a dominant negative effect. The growth inhibitory phenotype of the TORl (Ser-1972-lle) mutant may be due to the constitutive modification of aTOR effector, possibly due to an activating influence of the isoleucine group on the kinase of TORl. Changes in the conserved serine residue may provide a conformational basis for kinase activation. Ser-1972 and its flanking sequences are found in the kinase domain of FRAP and TOR proteins, but not in the kinase domains of the known PI kinases. Thissequence may be analogous to ones found in the regulatory domains of the serinel threonine kinases PKG and PKC (these domains are also immediately N-terminal to the kinase domains) and the homologous regulatory subunits RI and RII of PKA. Studies of these protein kinases indicate that the putatively analogous sequences act as inhibitory pseudosubstrates, interacting directly with the kinase active site. A striking similarity in the kinases of the FRAP/TOR family and the CAMP-dependent protein kinase PKA is that in both instances the key serine residue in the regulatory domain can be mutated to alanine without removing the binding properties of the domains, while mutation to larger residues results in potent inhibition of binding (Buechler and Taylor, 1991) . Ourobservationssuggest that Ser-1972 and its surrounding FRB domain may be behaving in a way that is analogous to the RII subunit of PKA and the N-terminal regulatory subunit of PKG.
The TOR poteins are functionally and structurally related, yet they also have distinguishing features. The C-terminal kinase domains of the TOR proteins can be interchanged without loss of function (Helliwell et al., 1994) , and certain mutations at the conserved serine in their FRB domains in either protein allow yeast to resist the actions of rapamycin dominantly. Double disruption of TON and TOR2 results in Gl cell cycle arrest, and as shown above, in both cases their Gl function requires an active kinase domain. In addition, the dominant negative TORl kinasedead mutant arrests the cell cycle in Gl , as does rapamycin. These results suggest that the kinase domains of both proteins share a common Gl function. But, although the loss of TOR7 only slightly affects yeast cell growth, the loss of TOR2 is lethal and results in random cell cycle arrest (Kunz et al., 1993) . The dominant nature of the FRB domain mutations in TORl , which allow yeast to proliferate even though both endogenous TORsare inhibited by rapamycin, suggests that the mutations may lead to a gain of TORl function that complements the functions of TOR2. Although rapamycin inhibits at least the Gl function of the TOR2 protein as evidenced by the rapamycin sensitivity of a tori null strain (see above), and TOR2 is an essential gene, rapamycin-treated yeast harboring the TORl (Ser1972+Arg) mutation do not show the tor2 null lethal phenotype, suggesting specifically that the TOR7 mutation may suppress this phenotype. An alternative explanation is that rapamycin might inhibit only a subset of the functions of TOR2 and that in the presence of rapamycin its essential function is still intact. This is indeed suggested by the finding that the rapamycin-treated tofl null strain is observed to arrest specifically in Gl, suggesting that rapamycin might target only the Gl function of the TOR2 protein and not its essential function. To test this, we studied whether a dominant rapamycin-resistant TOR7 mutant could suppress the lethality of a for2 null mutation. Tetrad analyses with diploid yeast containing a heterozygous TOR2 allele (TOR2/.4for2) in either a wild-type TOR7/TOR7 or homozygous mutant TOR7 (Ser-1972+Arg)/TOR7 (Ser1972+Arg) background revealed that in either genetic background, the tor2 null is lethal. Thus, although rapamycin inhibits the Gl function of the TOR2 protein, it does not inhibit a second, essential function of the protein. We tested whether this TOR2 essential function requires an intact kinase domain by complementing the tor2 null with plasmid-born wild-type or kinasedead mutant TOR2-TO/?7 fusion genes. Only those genes with an intact kinase domain were able to rescue the lethality associated with the TOR2 disruption. Thus, this essential TOR2 function also requires a functional kinase domain. Since both rapamycin-sensitive and -insensitive functions of TOR2 require a functional kinase domain, FKBPI 2-rapamycin does not appear to inhibit directly the kinase activity of TOR proteins.
A model that explains the dual functions of the kinase domain in TOR2 is shown in Figure 7 . Distinct effecters for the Gl and essential functions of TOR2 may associate with separate domains of TOR2. We propose that the Gl effector binds to the C-terminal conserved domain, while the effector for the essential function binds to the unique N-terminal domain. Presumably, the Gl effector is able to bind to the same region of the TORl protein. The effectors may be involved in localization, where a thus far hidden TOR2 lipid kinase activity could be envisioned, may be modulated by a phospholipid and/or adenine nucleotide complex involving the kinase domain, in analogy to guanine nucleotide complexes of guanine nucleotidebinding proteins, or most simply may be a substrate for a The TOR2 protein has at least two functions that require an intact kinase domain. Only its Gi function is sensitive to rapamycin. We propose that FKSPIP-rapamycin interferes with the association or phosphorylation of a Gi effector of both TORl and TOR2, but not an effector of the essential function of TOR2.
protein kinase activity in TOR2. Since FKBPl2-rapamycin does not appear to inhibit the catalytic activity of the kinase of TOR2 in a general way, it may instead selectively prevent the Gl effector from binding to or being phosphorylated by TOR2.
TOR proteins and their mammalian FRAP homologs mediate mitogenic signaling pathways distinct from the Ras-MAPK and, in mammalian cells, Jak-Stat pathways. The present work reveals that TORl and TOR2 are complex, multidomainal proteins that use their kinase activities to effect multiple cell cycle functions, and it provides insights into the mechanism by which FKBPlP-rapamycin inhibits Gl cell cycle progression.
Experlmental Procedures Yeast Strains and Genetlc Methods
Standard procedures for culturing and mating strains, diploid isolation, sporulation, and tetrad analyses were used (Guthrie and Fink, 1991) .
S. cerevisiae strains used in this study are listed in Table 2 . The two yeast haploid strains carrying the Ser-1972+Arg mutation in TORf and Ser-1975+Arg mutation in TOR2, respectively, were derived from YFKO07 (Briruela et al., 1991) by integrating an approximately 900 bp PCR products containing either Ser-1972eArg (AGC to AGG) in 7OR7 or Ser-1975+Arg (AGT to AGG) in TOR2. These were confirmed by sequencing.
An HO gene in pOLl6 was used to construct wild-type or homozygous mutant diploid YFKOO7 yeast strains from corresponding haploid yeast strains.
Away for TOR I Memctkms wlth FKBP12-Ftapamycln
To purify yeast FRB proteins from yeast S. cerevisiae, approximately 0.5 lb of baker's yeast was lysed with glass beads in TSSN+ (50 mM Tris-HCI, 150 mM NaCI, 5 mM NaF, 1 mM N&VO,, 1 @ml leupeptin, 1 @ml aprotinin, 1 &ml trypsin inhibitor, 1 mM PMSF. 1 mM DlT, 1% NP40 (pH 7.5)). Lysates were cleared twice by centrifugation for 30 min at 25,000 x g at 4OC. The pH of the supernatant was adjusted to 7.5 with 1 N NaOH. The lysate was then loaded onto a Mono Q column. After extensive washing with TBSN+, the bound material was eluted with 1 M NaCl TSSN+ and the eluant was equally divided into three fractions, each of which was incubated with 0.7 PM yGFK alone, yGFK-FK505, or yGFK-rapamycin for 15 min at 4X and loaded onto glutathione SSepharose cdumn (GTS, Soehringer). After washed with 1 M NaCl TBSN+ extensively, the GTS-bound material was eluted into 2 x protein gel sample buffer, separated on SDS-polyacrylamide 5'-CG GGA TCC GCC ATG GTT CAG GAA GAG ACT-3' and 5°C CGA ATT CTA GAT ATC CAA ATG TCT CTT GAA-3'. The amplified DNAs were subcloned into pETSa. This plasmid was then linearized with EcoRl and used for in vitro transcription.
Isolation of TORI and TOR2 Genes from S. -revMae A genomic DNA library was constructed in pRS315 from a spontaneous dominant rapamycin-resistant yeast mutant and was introduced into a wild-type, rapamycin-sensitive yeast strain. A plasmid that conferred resistance to 100 nM rapamycin was recovered and found to be identical to the TOR7 gene, except with a mutation converting Ser-1972 to isoleucine. The corresponding wild-type TOR7 gene was isolated by gap repair of Bgllltut plasmid in wild-type yeast. The TOR2 genes were isolated similarly. To introduce a convenient restriction site for subcloning, the wild-type and mutant TORl plasmids were replaced at the 5' end with a Sacl site followed by the second amino acid of TORl using PCR with the following pair of primers: 5%AG CTC TTG AAC CGC ATG AGG AGC AGA TIT GG-3' and 5"ACG GGG CCC AAG GGA ACT GCC-3'. The PCR product was digested with Sacl-Spel and was used to replace the same restriction fragment of the original genomic clones.
Immunological Techniques
To generate TORl-specific antiserum, the GST-TORl (1223-2361) was expressed as inclusion bodies, purified conveniently by washing the cell pellets after lysis, and injected into rabbits. After boosting twice with antigens, the antisera tested positive for TORl on a Western blot. Western blot analyses were carried out as decribed previously (Harlow and Lane, 1966) . Antigens were detected using the ECL method (Amersham). The anti-TORl serum was used at a dilution of 1 :lOOO. The anti-flu hemaglutinin monoclonal antibody, MAb 12CA5, was used at 1:300 dilution. For immunoprecipitation, cell lysates were incubated with MAb 120% antibody at a dilution of 1300 for 1 hr at 4%. The immunocomplexes were captured with protein G-conjugated Sepharose by incubating for another hour at 4%, washed three times with TBSN+, and three times with TBS plus 1 mM DlT. The final immunoprecipitates were either directly used for in vitro kinase assays, or were eluted into SDS protein sample buffer for Western blot analyses.
TORT Expresslon Plasmld Constructs and In Vltro Mutagenesis
To create a galactose-inducible yeast expression vector, the G6PD promoter region of pG-1 (2 NM, TRP) (Schena et al., 1991) was inserted into the BamHl site with the following oligo sequence encoding an 5' HA epitope: 5'-T ACC ATG GGA TAC CCA TAC GAT GlT CCA GAT TAC GCT TGG TAC CAT GGA GCT CGA GTC GAC GGA C-3' and 5°C GTC GAC TCG AGC TCC ATG GTA CCA AGC GTA ATC TGG AAC ATC GTA TGG GTA TCC CAT GGT AGA TC-3'. The Smal-Sacl fragment containing the G6PD promoter of the HA epitope-modified pG1 was replaced with a Xhol (blunted)-Sacl fragment containing the GAL70 promoter from YCPIFI 5. The full-length TORl was then cloned into this expression vector with a HA tag on its immediate 5' end. To introduce mutations at Ser-1972, the Sacll-Kpnl fragment of TORl was subcloned into pBluescript SK(+) (Stratagene) (pBluescript TORlSK).
In vitro phagemid mutagenesis was carried out with the following primers: Ser-1972-Ala, 5'-ATGTTCAACGAGCGGGCCGCATClTCCAGTCCTTCA-3'; Ser-1972+Glu, 5'ATGTTCAA--CGAAAAATTGGCGlTCCGCATCTTCCAGTCClTC-3'; Ser-1972-Arg, 5'-GlTCAACGAAAAA~GGCG~CTCGCATCITCCAGTCCT-3'. The mutant DNA was inserted back into the full-length TORl gene by subcloning the Ncol-Kpnl mutant fragment into the HA-tagged TORl construct.
To introduce kinase inactivation mutations into TORl, the Kpnl-Sall fragment of TORl was subcloned into pBluescript KS(+). In vitro mutagenesis was carried out as above with the following primers: Arg-2276+Pro, S'CTGGGACTAGGTGATC~CCATCCAAGCAA-CCTG-3'; Asp2294+Glu, 5%lTATCCACATTGA&lXGGCGAlTG-lllTGA-3'.
To reconstruct the full-length Arg-2276 and the Asp-2294 mutant TORl gene, the Kpnl-Sall DNA fragments from the TOR7 mutant mutagenesis constructs were excised, purified, and subcloned back into the HA-tagged wild-type or mutant TOR7. All mutations were confirmed by DNA sequencing. To construct TOR2-TORl mutants, the BamHI-Pstl fragment of wild-type and mutant TORl, which contains codons 1661-2470 and the 3'-noncoding sequences of TORl, were excised from the above TORl expression construct and fused with a TOR2 genomic DNA containing the upstream promoter region and codons 1-1666 in pRS315.
The TORl-45 wild-type and mutant DNA fragments were subcloned into the BamHI-EcoRI sites of pYES (2 PM, GALl) (Invitrogen).
Testing Growth PropertIes of Yeast Strains
To test the growth of yeast strains on plates, freshly grown yeast colonies were streaked onto selection plates containing either glucose or galactose in the presence or absence of 100 nM rapamycin and incubated for 3-4 days at 30%. To test the growth of yeast strains in liquid culture, yeast cells were first grown overnight in glucose selection medium, diluted into YP-sucrose medium at OD, = 0.25, and incubated for 2 hr at 30%. Cells were pelleted and resuspended into YP-galactose medium. Cells were incubated at 30% with shaking. Aliquots of 1 ml culture were drawn at different times for OD measurements at 800 nM.
TORI and TOR2 Dlaruptlona
The TORI disruption vector was constructed by inserting the BglllSglll fragment from YEpl3 containing the LEM selection marker gene into the BamHl site of TORI in pBluescript TORlSK.
The gene disruption construct was linearized and transform into haploid YKFOO7 strain selecting for leucine (tor7::LEf.Q) prototrophy.
The disruption of the TORI locus was confirmed by PCR analyses of genomic DNA prepared from these LEU2'clones with one TORI primer (5'-AAC GCC AGA GAT lTG CTT GTGS') and with one LEU2 primer (5'-GAT ClT Cl-T AGG GGC AGA CAT-3').
The Sphl-Smal fragment of TOR2 was subcloned into pTZl8 (SioRad) vector to give pTz-TOR2SS.
The TOR2 disruption vector was constructed by inserting eitherthe same Bglll-Bglll fragment of aLEU2 marker gene as above, or a Bglll-BamHI fragment that contains a HEG-URA-HISG marker gene cassette from PNKY51 into the SamHl site of TOR2. The LEU2 disruption plasmid was linearized and transformed into diploid wild-type YFKoO7 (MATa/a TORI/TOR1) or homozygous TORI (Ser-1972*Arg) mutant (MATala TORI [Ser-1972+Argy TOR7 [Ser-1972+Arg]) selecting for leucine or uracil prototrophies. The HI.%&URA-HISG disruption construct was linearized and introduced into a diploid strain NKY260. The heterozygous disruption of the 7OR2locus wasconfirmed by PCRanalysesofthe TOR2disruption with one TOR2 primer @'-GAG GTA GAA lTC lTA GAA GAGS'), one EU2 primer (5%AT CIT ClT AGG GGC AGA CATJ'), or one HlSG primer (6'-TAA GCG GOT GGT GTC TAA CAT-3'). Diploid strains heterozygous for TOR2 disruption were sporulated by patching yeast cells onto sporulation medium and incubating at room temperature and were dissected on YPD. After viable spores formed colonies on YPD plates, replica plates were made with synthetic medium for testing cosegregation of the selective markers.
Complementation of the Temperature Sensitivity of a forf Mutant Strain A Xhol-SamHI fragment (nucleotides 1289-2473) and Sacll-SamHI fragment (nucleotides 39016348) of TORI were cloned in a three part ligation into pRS304 (Sikorski and Hieter, 1989) to create pYDF79. pYDF79 was linearized with BamHl and transformed into YMWl (M. Wahlberg, University of Texas Southwestern). A transformant was picked for Southern blot analysis to confirm that it does contain a tori deletion. This mutant grows about 80% as fast as the wild-type strain at 24% and 30% but is arrested at 37%
